ArticleBiotechnology and bioengineering2026
Improved Messenger RNA Stability and Biocompatibility Through Self-Gelatinizable Nucleic Acids.
Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Recent advances in the chemical synthesis and modification of messenger RNA (mRNA) have generated growing interest in mRNA-based therapeutics. However, the inherent instability of mRNA in vivo and during storage remains a major challenge, requiring the development of safe and effective delivery systems. Lipid nanoparticles (LNPs) currently serve as the primary vehicle for mRNA delivery, with well-documented clinical success. Nevertheless, immunogenicity associated with certain components underscores the need for biocompatible alternatives. To address these stability and safety concerns, we developed an mRNA-loaded DNA hydrogel based on self-gelatinizable nucleic acid technology. The hydrogel is formed through the self-assembly of designed DNA units and provides an inherently biocompatible framework. mRNA loaded into the hydrogel exhibited sustained protein expression in myofibroblasts due to controlled mRNA release, while inducing negligible proinflammatory cytokine production or cytotoxicity in antigen-presenting cells. Additionally, the hydrogel markedly enhanced mRNA resistance to both nuclease degradation and storage-induced degradation. These findings demonstrate that mRNA-loaded DNA hydrogels can serve as a promising, biocompatible platform for next-generation mRNA therapeutics, achieving both enhanced stability and reduced immunogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.